Lifesci Capital Reaffirms “Market Perform” Rating for Rapt Therapeutics (NASDAQ:RAPT)

Rapt Therapeutics (NASDAQ:RAPT)‘s stock had its “market perform” rating reissued by stock analysts at Lifesci Capital in a report released on Tuesday,Benzinga reports.

A number of other analysts have also issued reports on RAPT. Barclays reduced their price target on shares of Rapt Therapeutics from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. Guggenheim cut shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. Piper Sandler lowered Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 price objective for the company. in a report on Tuesday. Wells Fargo & Company reissued an “equal weight” rating and set a $58.00 price objective on shares of Rapt Therapeutics in a research report on Tuesday. Finally, Cowen lowered shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $48.22.

Rapt Therapeutics Stock Performance

Shares of NASDAQ:RAPT traded up $22.45 during mid-day trading on Tuesday, hitting $57.55. The stock had a trading volume of 29,611,541 shares, compared to its average volume of 2,691,506. The company’s 50 day moving average is $32.75 and its 200-day moving average is $23.37. Rapt Therapeutics has a 12-month low of $5.67 and a 12-month high of $57.61. The company has a market cap of $1.59 billion, a PE ratio of -5.20 and a beta of 0.45.

Rapt Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.23. On average, equities research analysts predict that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.

Institutional Trading of Rapt Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP lifted its holdings in shares of Rapt Therapeutics by 173.4% during the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company’s stock valued at $1,170,000 after purchasing an additional 28,782 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Rapt Therapeutics in the third quarter valued at approximately $1,326,000. SummitTX Capital L.P. bought a new stake in shares of Rapt Therapeutics in the third quarter worth $2,370,000. Invesco Ltd. acquired a new position in Rapt Therapeutics during the third quarter worth $3,625,000. Finally, Boone Capital Management LLC acquired a new stake in Rapt Therapeutics in the 3rd quarter valued at $20,180,000. 99.09% of the stock is owned by institutional investors.

Key Stories Impacting Rapt Therapeutics

Here are the key news stories impacting Rapt Therapeutics this week:

• Positive Sentiment: GSK agreed to buy RAPT for ~$2.2 billion (~$58.00 per share), giving RAPT shareholders a near‑term cash exit and driving the stock rally. GSK to buy RAPT Therapeutics for $2.2 billion
• Positive Sentiment: Deal rationale: GSK gains access to RAPT’s late‑stage food‑allergy treatment, supporting strategic value and justifying the takeover premium. RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition
• Neutral Sentiment: TD Cowen reaffirmed a “hold” on RAPT — a muted analyst reaction that neither amplifies nor contradicts the deal’s valuation for shareholders. Benzinga
• Neutral Sentiment: HC Wainwright downgraded RAPT from “buy” to “neutral” with a $58 price target — effectively pricing the stock at the announced deal level and implying little or no incremental upside beyond the offer. RAPT just downgraded at HC Wainwright
• Negative Sentiment: Two investor‑rights firms (Ademi LLP and Halper Sadeh LLC) launched investigations into whether the $58 per‑share sale is fair to RAPT shareholders — potential legal challenges or shareholder litigation could delay closing or pressure deal terms. Ademi investigates fairness of RAPT transaction Halper Sadeh investigates fairness of RAPT sale

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.